Skip to content

蝴蝶网络

US · BFLY #2650 按市值排名 上市于 1970
7.25 -0.60 -7.64%
实时 - 追踪5344个代码 - 心跳于23秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 12.24 高于历史水平 第98百分位
5年平均 2.99 · 在Medical Devices中排名第114/125
市盈率 -30.00 低于历史水平 第2百分位
5年平均 -7.44 · 前瞻 -61.29
市销率 20.66 高于历史水平 第97百分位
5年平均 7.77 · 前瞻 17.41 · 在Medical Devices中排名第124/136

同业对比 Medical Devices

公司 市值 市盈率(TTM) 市净率 股息率
蝴蝶网络 (BFLY) 1.93B -25.00 10.20 0.00%
Abbott Laboratories (ABT) 181.50B 33.94 3.55 2.33%
Medtronic (MDT) 121.20B 23.34 2.41 3.01%
Stryker Corp (SYK) 113.02B 30.53 4.71 1.18%
Boston Scientific (BSX) 64.33B 17.97 2.58 0.00%
Edwards Lifesciences (EW) 49.92B 50.35 4.70 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值8.05 经济护城河None 不确定性High

当前股价低于晨星合理价值估算11.1%。

合理价值

Butterfly Network Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 17% premium over our quantitative fair value estimate of $8.05 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's lack of profitability undermines our estimated fair value. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its sales yield of 4.9%, which ranks in the bottom 10% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our view that shares are overvalued.

The firm's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 8.0%, a core component of valuation, falls in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

经济护城河

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

蝴蝶网络 讨论区 0 条评论

发表评论